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Staphylococcal exotoxins (SE) are among the most common etiological agents that cause vomiting, diarrhea, skin desquamation, fever, and toxic shock (1, 2, 13) . Staphylococcal toxic shock syndrome toxin 1 (TSST-1) and the distantly related staphylococcal enterotoxins A and B (SEA and SEB, respectively) are superantigens that potently stimulate T-cell proliferation and cytokine production (5) . These toxins bind with high affinity to the major histocompatibility complex (MHC) class II molecules on antigen-presenting cells (APC) and subsequently interact with specific V␤ regions of the T-cell antigen receptors (3, 5, 13, 14) . In vitro and in vivo studies show that these superantigens induce high levels of a variety of proinflammatory mediators, including tumor necrosis factor alpha (TNF-␣), interleukin 1 (IL-1), IL-6, and gamma interferon (IFN-␥) (5, 6, 11, 12, 15) . Both TNF-␣ and IL-1 have potent immunostimulating activities (8) . They promote leukocyte cellular interactions by increasing the expression of MHC class II as well as adhesion molecules. In addition, TNF-␣ and IL-1 also activate endothelial cells, increase procoagulant activities, and promote tissue injury. These cytokines act synergistically to enhance immune reactions. Consequently, these cytokines are pathogenic when present at high concentrations in vivo and are responsible for fever and toxic shock induced by SE.
Previous studies identified the involvement of other cell surface molecules on both T cells and APC in the interaction with superantigens (4, 7, 9) . It is not known to what extent the interaction of MHC class II and CD4 contributes to the production of these cytokines. Recently, a computational analysis was used to deduce the interactions between MHC class II on APC and CD4 on T lymphocytes (10) . Based on the contact residues, small nonpeptidic molecules were then synthesized to block the interactions of these cells. One such compound, TJU103, was immunosuppressive and was useful for inhibiting graft rejection (10) . This study was undertaken to determine the effect of TJU103 on staphylococcal superantigen-induced T-cell activation and cytokine production from human peripheral blood mononuclear cells (PBMC).
Purified SEA, SEB, and TSST-1 were obtained from Toxin Technology (Sarasota, Fla.). The endotoxin content of these preparations was Ͻ1 ng of endotoxin/mg of protein, as determined by the Limulus amoebocyte lysate assay (BioWhittaker, Walkersville, Md.). Human recombinant TNF-␣ (rTNF-␣), peroxidase-conjugated anti-rabbit immunoglobulin G (IgG), and peroxidase-conjugated anti-goat IgG were obtained from Boehringer Mannheim (Indianapolis, Ind.). Antibodies against human TNF-␣ (hTNF-␣) and hIL-6 were purchased from R&D Systems (Minneapolis, Minn.). Human rIL-1␤ was kindly provided by J. Oppenheim (National Cancer Institute, Frederick, Md.). Human rIFN-␥, rIL-6, and antibodies against hIL-1␤ were obtained from Collaborative Research (Boston, Mass.). Anti-hIFN-␥-and IgG, with and without biotin, were obtained from Pharmingen (San Diego, Calif.). TJU103 was obtained from Calbiochem (San Diego, Calif.) and was dis-solved in dimethyl sulfoxide (DMSO). All other reagents were from Sigma (St. Louis, Mo.).
Human PBMC were isolated by Ficoll-Hypaque density gradient centrifugation of heparinized blood from healthy human donors. Among the 12 donors tested, the magnitude of inhibition of the SE-induced cytokine production or T-cell proliferation in response to TJU103 was very consistent in all. PBMC (10 6 cells/ml) were cultured at 37°C in 24-well plates containing RPMI 1640 medium and 10% heat-inactivated fetal bovine serum. Cells were incubated with either SEA, SEB, or TSST-1 (100 ng/ml) for 16 h, and the supernatants were harvested and analyzed for TNF-␣, IL-1␤, IL-6, and IFN-␥. Cytokines were measured by enzyme-linked immunosorbent assay with cytokine-specific antibodies according to the manufacturer's instructions (6, 7) . Recombinant cytokines (20 to 1,000 pg/ml) represented the standards for calibration, and the detection limit of all assays was 20 pg/ml. The cytokine data are expressed as the mean readings Ϯ standard deviations (SD). TJU103, when present, was added simultaneously with the exotoxins. For T-cell proliferation assays, PBMC (10 5 cells/ well) were plated in triplicate with SEA, SEB, or TSST-1 (100 ng/ml), with or without TJU103, for 48 h at 37°C in 96-well microtiter plates. Cells were pulsed with 1 Ci of [ 3 H]thymidine (New England Nuclear, Boston, Mass.) per well during the last 5 h of culture as previously described (6, 7) . Cells were harvested onto glass fiber filters, and incorporated [ 3 H]thymidine was measured by liquid scintillation. All data were analyzed for significant differences by the Student t test with Stata software (Stata Corp., College Station, Tex.). Differences between TJU103-treated and untreated control groups were considered significant if P was Ͻ0.01.
The production of TNF-␣ and IFN-␥ by SEB-stimulated PBMC in the presence of different concentrations of TJU103 was first examined. Figure 1 shows that TJU103 blocked the production of TNF-␣ and IFN-␥ from PBMC incubated with SEB in a dose-dependent manner, reducing TNF-␣ and IFN-␥ by 76 and 92%, respectively, at 0.5 to 1 mM TJU103. The optimal concentration of TJU103 was 0.5 mM. At 1 mM TJU103, toxicity to cells was apparent as cell viability as determined by the trypan blue test was only 50%. This toxic effect was a direct result of the high concentration of the DMSO (0.52%) present in the TJU103 preparation. Cell viability in the presence of control medium of 0.52% DMSO without TJU103 was also 50%. TJU103 was nontoxic at 0.5 mM (viability of Ͼ90%) and was chosen for subsequent experiments. Lower concentrations of TJU103 (Ͻ0.2 mM) inhibited TNF-␣ and IFN-␥ by only Ͻ45 and Ͻ37%, respectively.
The effect of TJU103 on the production of other proinflammatory cytokines (IL-1␤ and IL-6) by SEA-, SEB-, and TSSTstimulated PBMC was next examined (Fig. 2) . At 0.5 mM TJU103, TNF-␣ was reduced by 60, 69, and 68% in SEA-, SEB-, or TSST-1-treated cells, respectively. TJU103 similarly decreased the levels of IL-1␤, IL-6, and IFN-␥ by Ͼ56, Ͼ76, and Ͼ72%, respectively, in SE-stimulated cells.
In addition to increasing cytokine levels, superantigens are also potent activators of T-cell proliferation. Therefore, the effect of TJU103 on SE-induced proliferation of T cells was investigated. Figure 3 shows that TJU103 significantly decreased (95 to 99%) superantigen-induced proliferation of T cells. Lower concentrations of TJU103 (0.2 mM) also effectively inhibited T-cell proliferation (Ͼ90% [data not shown]).
This study demonstrated that TJU103 effectively inhibited superantigen-mediated production of TNF-␣, IL-1␤, IL-6, and IFN-␥ by human PBMC in vitro. Downregulation of proinflammatory cytokines by TJU103 in SEA-, SEB-, and TSST-1stimulated PBMC suggested that blocking the interaction of MHC class II and CD4 can drastically decrease proinflammatory cytokine induction and T-cell proliferation by staphylococcal superantigens. Preliminary experiments indicated that TJU103 does not inhibit proinflammatory cytokine production by endotoxin-activated monocytes. Thus, TJU103 has anti-inflammatory effects and interferes with the activation of both T cells and APC, as monocyte-derived cytokines (IL-1␤, TNF-␣, and IL-6) as well as T-cell cytokines (IFN-␥, TNF-␣, and IL-6) were inhibited.
In conclusion, the promising findings of this study suggest that TJU103 is a potential therapeutic agent to mitigate SEA-, SEB-, and TSST-1-mediated shock in humans.
